FIT Biotech is engaged especially in researching and developing an HIV vaccine. The project against the HI virus has been supported by several grants and by extensive international scientific collaboration in order to help fight the human immunodeficiency virus – and to make a difference with the help of biotechnological innovations.
Today FIT Biotech's headquarters is located in Tampere, Finland, where it also has a cGMP approved production facility.
FIT Biotech's long-term vision is to continue developing
the selected vaccines and gene therapies based on the
company’s innovative proprietary gene delivery technology
(GTU®). FIT Biotech has become a globally renowned name in
the fields of vaccines and DNA delivery technology.
Inveni Secondaries Management Oy
Other Finnish institutional Investors and Individuals
Rabbe Slätis, Chairman
Markku Fagerlund, Member
Erkki Pekkarinen, Member
Dirk Teuwen, Member
Juha Vapaavuori, Member